Morgan Stanley
RVLP

Morgan Stanley’s RVL Pharmaceuticals plc Ordinary Shares RVLP Stock Holding History

Morgan Stanley’s Portfolio RVLP Stock Details RVLP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-32,000
Closed -$2.77K – 8035
2023
Q3 		$2.77K Sell
32,000
-957,280
-97% -$276K ﹤0.01% 7057
2023
Q2 		$554K Sell
989,280
-68,278
-6% -$60.2K ﹤0.01% 5155
2023
Q1 		$1.21M Sell
1,057,558
-39,075
-4% -$46.9K ﹤0.01% 4747
2022
Q4 		$1.23M Sell
1,096,633
-76,571
-7% -$122K ﹤0.01% 4746
2022
Q3 		$2.46M Sell
1,173,204
-47,549
-4% -$92.4K ﹤0.01% 4282
2022
Q2 		$1.66M Sell
1,220,753
-53,164
-4% -$77K ﹤0.01% 4673
2022
Q1 		$2.15M Sell
1,273,917
-92,111
-7% -$132K ﹤0.01% 4468
2021
Q4 		$1.48M Sell
1,366,028
-56,747
-4% -$92.1K ﹤0.01% 4802
2021
Q3 		$4.2M Sell
1,422,775
-245,876
-15% -$826K ﹤0.01% 3921
2021
Q2 		$5.02M Sell
1,668,651
-262,130
-14% -$802K ﹤0.01% 3773
2021
Q1 		$6.29M Buy
1,930,781
+691,486
+56% +$2.84M ﹤0.01% 3168
2020
Q4 		$5.11M Buy
1,239,295
+977,151
+373% +$5.63M ﹤0.01% 3235
2020
Q3 		$1.42M Buy
262,144
+243,746
+1,325% +$1.4M ﹤0.01% 3951
2020
Q2 		$124K Buy
18,398
+265
+1% +$1.3K ﹤0.01% 5300
2020
Q1 		$57K Sell
18,133
-73,262
-80% -$390K ﹤0.01% 5422
2019
Q4 		$639K Buy
91,395
+48,654
+114% +$260K ﹤0.01% 4788
2019
Q3 		$164K Buy
42,741
+11,446
+37% +$38.8K ﹤0.01% 5236
2019
Q2 		$119K Sell
31,295
-19,312
-38% -$64.2K ﹤0.01% 5245
2019
Q1 		$182K Buy
50,607
+26,796
+113% +$197K ﹤0.01% 5114
2018
Q4 		$185K Buy
+23,811
New +$191K ﹤0.01% 5313

Other funds holding RVLP

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

Morgan Stanley's RVLP Position: Q4 2023 in Review

Morgan Stanley sold out of RVL Pharmaceuticals plc Ordinary Shares (RVLP) in Q4 2023, closing a stake of 32,000 shares — an estimated $2.77K sold.

Morgan Stanley first reported a position in RVLP in Q4 2018 and held it in 20 quarters. The position peaked at $6.29M in Q1 2021. 3 funds tracked by Wall St. Rank hold RVLP as of Q4 2023.

  • Morgan Stanley reported no remaining RVL Pharmaceuticals plc Ordinary Shares position as of Q4 2023 after selling out during the quarter.
  • Morgan Stanley sold 32,000 RVL Pharmaceuticals plc Ordinary Shares shares in Q4 2023, an estimated $2.77K.
  • Morgan Stanley first reported a position in RVL Pharmaceuticals plc Ordinary Shares in Q4 2018 and held it in 20 quarters.
  • Morgan Stanley's RVL Pharmaceuticals plc Ordinary Shares position peaked at $6.29M in Q1 2021.
  • 3 funds tracked by Wall St. Rank held RVL Pharmaceuticals plc Ordinary Shares as of Q4 2023.

Based on Morgan Stanley's 13F filing for Q4 2023, filed 13 Feb 2024.